Related Experiment Videos
[Clinical study of cefmenoxime in the field of abdominal surgery]
Abstract:
The effect of cefmenoxime (CMX) was evaluated in the abdominal surgery at 18 hospitals on the prevention and the treatment of postoperative infections. The results were summarized as follows. In 179 patients with prophylactic use of 2-4 g of CMX a day, no postoperative infection was observed in 94.4%. Using fever index to judge the effect of CMX in prevention of postoperative infections, the value of fever index was higher in the infected group than in the non-infected group. A significant difference was also observed in mean fever index value between the groups given CMX in 2 g and 4 g daily, being 15.4 degree hours and 1.7 degree hours. The incidence of postoperative infections was higher in cases with intraoperative bleeding of more than 500 ml than in cases with less bleeding. Postoperative infection and peritonitis subsided after the administration of 2-4 g of CMX/day for more than 8 days in 77.1% of cases. Very few side effects were noted due to CMX. These results suggest that CMX is safe and effective in the field of abdominal surgery for the prevention of postoperative infections and in the treatment of postoperative infections.
Insights
Cefmenoxime (CMX) effectively prevents and treats postoperative infections in abdominal surgery, showing a 94.4% success rate in prophylaxis. This antibiotic is safe and beneficial for surgical patients, reducing infection incidence and severity.
Area of Science:
- Infectious Diseases
- Surgical Infections
- Pharmacology
Context:
- Postoperative infections pose a significant risk in abdominal surgery.
- Evaluating novel antibiotic efficacy is crucial for patient outcomes.
- Multicenter studies are vital for robust clinical evidence.
Purpose:
- To assess the efficacy and safety of cefmenoxime (CMX) in preventing and treating postoperative infections in abdominal surgery.
- To compare the effectiveness of different dosages of CMX.
- To identify factors influencing infection rates, such as intraoperative bleeding.
Summary:
- A multicenter study involving 179 patients demonstrated that prophylactic cefmenoxime (CMX) use (2-4 g/day) resulted in no postoperative infection in 94.4% of cases.
- A lower fever index correlated with CMX prophylaxis, with a significant difference observed between 2 g and 4 g daily doses.
- Treatment with CMX (2-4 g/day for >8 days) resolved postoperative infections and peritonitis in 77.1% of patients, with minimal side effects.
Impact:
- Cefmenoxime (CMX) is established as a safe and effective agent for both the prevention and treatment of surgical site infections in abdominal procedures.
- The study highlights the dose-dependent efficacy of CMX in reducing infection markers.
- Findings support the integration of CMX into perioperative protocols to improve patient safety and surgical outcomes.